drugset / Trial / NCT01110408

A Safety and Tolerability Study of Doripenem Compared With Cefepime in Children Hospitalized With Complicated Urinary Tract Infections

NCT01110408

Phase 3 Terminated 41 enrolled Janssen Research & Development, LLC
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety and tolerability of doripenem compared to cefepime in children hospitalized with complicated urinary tract infections.

Timeline

Start
2010-12
Primary completion
2013-06
Completion
2013-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Cefepime Small molecule 50 mg/kg Intravenous
Subject Doripenem Small molecule 20 mg/kg Intravenous
Background Amoxicillin/clavulanate potassium Unknown Oral